share_log

8-K: Current report

8-K: Current report

8-K:重大事件
美股SEC公告 ·  2024/11/14 06:11

Moomoo AI 已提取核心訊息

BeiGene announced on November 14, 2024, its intention to change its company name to "BeOne Medicines Ltd." The rebranding initiative reflects the company's commitment to developing innovative cancer medicines through global partnerships to serve patients worldwide. The new name will be accompanied by a change in ticker symbol to "ONC" on the Nasdaq Global Select Market.The proposed name change is subject to shareholder approval at an upcoming shareholder meeting. The company plans to file a definitive proxy statement with the SEC containing detailed information about the name change and related matters for shareholder consideration.
BeiGene announced on November 14, 2024, its intention to change its company name to "BeOne Medicines Ltd." The rebranding initiative reflects the company's commitment to developing innovative cancer medicines through global partnerships to serve patients worldwide. The new name will be accompanied by a change in ticker symbol to "ONC" on the Nasdaq Global Select Market.The proposed name change is subject to shareholder approval at an upcoming shareholder meeting. The company plans to file a definitive proxy statement with the SEC containing detailed information about the name change and related matters for shareholder consideration.
百濟神州於2024年11月14日宣佈,計劃將公司名稱更改爲"BeOne Medicines Ltd."。這一品牌重塑倡議反映了公司通過全球合作伙伴關係開發創新癌症藥物,以服務世界各地患者的承諾。新名稱將伴隨在納斯達克全球精選市場更改逐筆明細爲"ONC"。提議的名稱更改需在即將召開的股東會議上獲得股東批准。公司計劃向美國證券交易委員會(SEC)提交一份最終的代理聲明,其中包含有關名稱更改及相關事宜的詳細信息,以供股東審議。
百濟神州於2024年11月14日宣佈,計劃將公司名稱更改爲"BeOne Medicines Ltd."。這一品牌重塑倡議反映了公司通過全球合作伙伴關係開發創新癌症藥物,以服務世界各地患者的承諾。新名稱將伴隨在納斯達克全球精選市場更改逐筆明細爲"ONC"。提議的名稱更改需在即將召開的股東會議上獲得股東批准。公司計劃向美國證券交易委員會(SEC)提交一份最終的代理聲明,其中包含有關名稱更改及相關事宜的詳細信息,以供股東審議。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息